What happens next in GLP-1 — and when.

Get the briefing

What moved in the GLP‑1 field, in your inbox.

@glp1briefing

Indications › MASH / NAFLD › semaglutide

semaglutide in MASH / NAFLD

semaglutide is not approved in the US for MASH / NAFLD, and has 20 trials on file here in this condition. 7 of them are phase 3 or later. The next scheduled result is 2026-12. Being studied in a condition is not the same as being approved for it; most such programmes end without an approval.

20 registered trials study semaglutide (Rybelsus, Wegovy, Ozempic) in MASH / NAFLD, 9 of them still active and 2 in phase 3. The next is due to report 2026-12-31.

Trials on file
20
Active
9
Active phase 3
2
Participants in active trials
2,326
Sponsors
15
Scheduled readouts
4

Scheduled to report

Dates are filed by the sponsor and move often. Each links to its own record and change history.

Est. completionTrialPhaseParticipants
2026-12-31Semaglutide Treatment in the Real-world for Fibrosis Due to NAFLD in Obesity and T2DM
NCT06005012 · University of California, San Diego
P2120
2026-12-31A Study Comparing IBI362 vs Semaglutide in Chinese Overweight or Obese Adults With Metabolic Dysfunction-associated Fatty Liver Disease （MAFLD）
NCT06884293 · Innovent Biologics (Suzhou) Co. Ltd.
P3479
2027-04-30A Study of CS060380 Tablets in Patients With MASH and Obesity
NCT07466017 · Cascade Pharmaceuticals, Inc
P2130
2027-09-03Non-Alcoholic Fatty Liver Disease, the HEpatic Response to Oral Glucose, and the Effect of Semaglutide (NAFLD HEROES)
NCT03884075 · National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
P2104

All trials on file

Every registered trial of semaglutide grouped under MASH / NAFLD, largest first. Grouping follows the registry’s own condition wording.

TrialStatusPhaseSponsor
Research Study on Whether Semaglutide Works in People With Non-alcoholic Steatohepatitis (NASH)
NCT04822181
Active, not recruitingP3Novo Nordisk A/S
Research Study on Whether a Combination of 2 Medicines (NNC0194 0499 and Semaglutide) Works in People With Non-alcoholic Steatohepatitis (NASH)
NCT05016882
CompletedP2Novo Nordisk A/S
A Study Comparing IBI362 vs Semaglutide in Chinese Overweight or Obese Adults With Metabolic Dysfunction-associated Fatty Liver Disease （MAFLD）
NCT06884293
Active, not recruitingP3Innovent Biologics (Suzhou) Co. Ltd.
Study of Semaglutide, and Cilofexor/Firsocostat, Alone and in Combination, in Adults With Cirrhosis Due to Nonalcoholic Steatohepatitis (NASH)
NCT04971785
CompletedP2Gilead Sciences
A Clinical Study of Efinopegdutide in Participants With Precirrhotic Nonalcoholic Steatohepatitis (NASH) (MK-6024-013)
NCT05877547
CompletedP2Merck Sharp & Dohme LLC
Investigation of Efficacy and Safety of Three Dose Levels of Subcutaneous Semaglutide Once Daily Versus Placebo in Subjects With Non-alcoholic Steatohepatitis.
NCT02970942
CompletedP2Novo Nordisk A/S
Combined Active Treatment in Type 2 Diabetes With NASH
NCT04639414
CompletedP4German Diabetes Center
Semaglutide in Nonalcoholic Fatty Liver Disease
NCT05813249
CompletedP4Zagazig University
A Study of Efinopegdutide (MK-6024) in Participants With Nonalcoholic Fatty Liver Disease (NAFLD) (MK-6024-001)
NCT04944992
CompletedP2Merck Sharp & Dohme LLC
A Study of CS060380 Tablets in Patients With MASH and Obesity
NCT07466017
Active, not recruitingP2Cascade Pharmaceuticals, Inc
Semaglutide Treatment in the Real-world for Fibrosis Due to NAFLD in Obesity and T2DM
NCT06005012
Active, not recruitingP2University of California, San Diego
Fibrosis Lessens After Metabolic Surgery
NCT06374875
RecruitingP4The Cleveland Clinic
Safety, Tolerability, and Efficacy of Monotherapy and Combination Regimens in Participants With Nonalcoholic Steatohepatitis (NASH)
NCT03987074
CompletedP2Gilead Sciences
Non-Alcoholic Fatty Liver Disease, the HEpatic Response to Oral Glucose, and the Effect of Semaglutide (NAFLD HEROES)
NCT03884075
RecruitingP2National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
A Research Study on How Semaglutide Works in People With Fatty Liver Disease and Liver Damage
NCT03987451
CompletedP2Novo Nordisk A/S
Semaglutide Effects in Obese Youth With Prediabetes/New Onset Type 2 Diabetes and Metabolic Dysfunction-Associated Steatotic Liver Disease
NCT05067621
Active, not recruitingP2Yale University
Treating PCOS With Semaglutide vs Active Lifestyle Intervention
NCT03919929
CompletedP2/P3University of Colorado, Denver
Semaglutide vs Sitagliptin
NCT05195944
Enrolling by invitationP4University Health Network, Toronto
Study of Semaglutide for Non-Alcoholic Fatty Liver Disease (NAFLD), a Metabolic Syndrome With Insulin Resistance, Increased Hepatic Lipids, and Increased Cardiovascular Disease Risk (The SLIM LIVER Study)
NCT04216589
CompletedP2National Institute of Allergy and Infectious Diseases (NIAID)
Randomized Double Blinded Placebo-Controlled w/Semaglutide to Prevent Weight Gain After Liver Transplant
NCT05424003
RecruitingP2University of Virginia

See the full record for semaglutide, or every molecule being studied in MASH / NAFLD. These are registered trials, nothing more. Most drugs tested in a new condition never get approved for it, and plenty of these will report nothing useful.